All In Biotech

Drug Trial Radar · NCT04777331

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 586 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

586

Actual

Start

May 5, 2021

Primary completion

Sep 11, 2024

Study completion Jun 30, 2031

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Prothena Biosciences Limited
First posted
Mar 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

Conditions

  • Parkinsons Disease

Interventions

  • PrasinezumabDrug

    Prasinezumab will be administered as an IV infusion to participants Q4W.

  • PlaceboDrug

    Prasinezumab placebo will be administered to participants.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DBT Period: Time to Confirmed Motor Progression Event Assessed by Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IIITime frame: From study start to end of DBT period to at least 76 weeks

Locations

110 sites in 9 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Barrow Neurological Institute

    Phoenix, Arizona

  • Neurology Center of North Orange County

    Fullerton, California

  • UC San Diego

    La Jolla, California

  • Keck School of Medicine of USC

    Los Angeles, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • University of California San Francisco

    San Francisco, California

  • CenExel Rocky Mountain Clinical Research, LLC

    Englewood, Colorado

  • Institute for Neurodegenerative Disorders

    New Haven, Connecticut

  • JEM Research LLC

    Atlantis, Florida

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida

  • Renstar Medical Research

    Ocala, Florida

  • University of South Florida

    Tampa, Florida

  • Charter Research - Winter Park/Orlando

    Winter Park, Florida

  • Northwestern University Feinberg School Of Medicine

    Chicago, Illinois

  • Southern Illinois University, School of Medicine

    Springfield, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Quest Research Institute

    Farmington Hills, Michigan

  • Henry Ford Hospital

    West Bloomfield, Michigan

  • Dent Neurological Institute

    Amherst, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • The Movement Disorder Clinic of Oklahoma

    Tulsa, Oklahoma

  • University Pennsylvania Hospital

    Philadelphia, Pennsylvania

  • Texas Neurology PA

    Dallas, Texas

  • Baylor College of Medicine Medical Center

    Houston, Texas

  • Central Texas Neurology Consultants

    Round Rock, Texas

  • University of Vermont Medical Center

    Burlington, Vermont

  • Sentara Neurology Specialists

    Norfolk, Virginia

  • EvergreenHealth Investigational Drug Services

    Kirkland, Washington

  • Inland Northwest Research

    Spokane, Washington

  • Medizinische Universität Graz

    Graz, Austria

  • Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck

    Innsbruck, Austria

  • Klinik Ottakring

    Vienna, Austria

  • Toronto Memory Program

    Toronto, Ontario, Canada

  • Toronto Western Hospital

    Toronto, Ontario, Canada

  • Clinique Neuro Outaouais

    Gatineau, Quebec, Canada

  • Montreal Neurological Institute and Hospital

    Montreal, Quebec, Canada

  • Groupe Hospitalier Pellegrin

    Bordeaux, France

  • Groupement Hospitalier Est - Hôpital Neurologique

    Bron, France

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.